Replies to post #180 on Provectus Biopharmaceuticals Inc (PVCT)

[Gulfbreeze]

Provectus (PVCT) PV-10 Could Treat Most Forms of Cancer
By Justin · Monday, March 29th, 2010

http://theotcinvestor.com/provectus-pvct-pv-10-could-treat-most-forms-of-cancer-660/

Provectus Pharmaceuticals, Inc. (PVCT), which is developing a unique cancer-fighting drug in the same market as Genta Incorporated (GETA) and Dendreon Corporation (DNDN), sees its drug as effective against multiple types of cancer.

Provectus Pharmaceuticals, Inc. (PVCT), whose PV-10 drug is in Phase II trials targeting metastatic melanoma, could see effectiveness against many other types of cancer too. The unique process by which PV-10 targets irregular cancerous cells suggests an ability to kill multiple forms of the deadly disease, which equates to a much larger market for the drug.

Provectus’ PV-10 treatment uses a special dye called Rose Bengal, which has the unique ability to be absorbed by damaged cells. Since cancer cells are often irregular in many ways, PV-10 is able to penetrate the cell. Due to PH differences, these cancer cells continue taking in so much PV-10 that they shatter, which leads to the death of the cancerous cell.

As a result of this belief, Provectus has initiated its Phase I study of PV-10 for liver metastasis in October 2009, and has already completed a Phase I trial of PV-10 for breast cancer in July 2008. Meanwhile, PV-10’s robust safety profile means that it is typically allowed to be used on a “compassionate use” basis, which should quickly confirm its effectiveness.

Provectus’ PV-10 has also demonstrated a unique “bystander effect,” which could prove extremely beneficial for combating cancer. Scientists have observed immune cells being recruited following the destruction of the initial cancer cell, and these immune cells are circulated in the system and influence distant tumors as well.

Meanwhile, cancer continues to be a growing problem, particularly in the developed world. Last year, ReportBuyer forecast that the global market for pharmaceutical cancer treatments would reach $103.9 billion by 2010, which would be up from just $66.2 billion in 2007. Currently, Amgen leads the pack with $11.1 billion in cancer sales in 2007.

Given the positive results from Provectus’ recent PV-10 Phase II trials, investors may want to keep an eye on this company. Meanwhile, PV-10’s potential to combat other forms of cancer and even realize a “bystander effect” in patients makes it all the more valuable, if it is eventually commercialized after an FDA approval.